Pradžia › Opinis kolitas › Washington
Opinis kolitas klinikiniai tyrimai Washington
22 tyrimai dėl Opinis kolitas ieško dalyvių vietose Washington.
Miestai Washington
Oficialus tyrimo tekstas (anglų kalba)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Washington Gastroenterology - Tacoma ( Site 0295), Tacoma
Renkami dalyviai3 fazė
Visi amžiai · Visoms lytims · Atnaujinta 2026-10-02 · NCT06651281Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Washington Gastroenterology - Bellevue /ID# 283966, Bellevue
- Washington Gastroenterology - Tacoma /ID# 284143, Tacoma
- The Vancouver Clinic /ID# 280497, Vancouver
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-10-02 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- GI Alliance, Bellevue
Renkami dalyviai4 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-09-30 · NCT06581328A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- University of Washington School Medicine, Seattle
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-30 · NCT06598943A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- Site 004, Seattle
- Site 019, Tacoma
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-29 · NCT07012395A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-021, Bellevue
- Site US-029, Tacoma
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-29 · NCT07845487A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- GI Alliance Tacoma, Tacoma
Renkami dalyviai3 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT07196748A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
- Seattle Children's Hospital, Seattle
- MultiCare Health System, Tacoma
Renkami dalyviai2/3 fazė
Amžius nuo 2 iki 17 · Visoms lytims · Atnaujinta 2026-09-24 · NCT05076175Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Washington Gastroenterology - Tacoma, Tacoma
Renkami dalyviai3 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-24 · NCT06937086LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
- Washington Gastroenterology - Bellevue, Bellevue
Renkami dalyviai2 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-09-22 · NCT07186101LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
- Swedish Medical Center, Seattle
- Principle Research Solutions, Spokane
- Providence Sacred Heart Medical Center & Children's Hospital, Spokane
- ir dar 1
Renkami dalyviai2 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-09-22 · NCT07415044A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- Washington Gastroenterology- GIA, Tacoma
Renkami dalyviai4 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-09-21 · NCT06095128A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- The Vancouver Clinic Inc. P.S. - Site Number: 8400090, Vancouver
Renkami dalyviai3 fazė
Amžius nuo 16 iki 80 · Visoms lytims · Atnaujinta 2026-09-15 · NCT07185009A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
- GI Alliance Tacoma, Tacoma
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-28 · NCT07577856Familial Inflammatory Bowel Disease Early Risk
- Seattle Children's Hospital, Seattle
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 0 iki 55 · Visoms lytims · Atnaujinta 2026-08-28 · NCT07791862A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
- University of Washington, Seattle
- Digestive Health Specialists, Tacoma
Renkami dalyviai2 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-08-21 · NCT06636656An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- GI Alliance - Bellevue - Site Number: 8400143, Bellevue
- The Vancouver Clinic Inc. P.S. - Site Number: 8400090, Vancouver
Renkami dalyviai3 fazė
Amžius nuo 16 iki 80 · Visoms lytims · Atnaujinta 2026-08-20 · NCT07184996A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- MultiCare Institute for Research & Innovation, Tacoma
Renkami dalyviai3 fazė
Amžius nuo 2 iki 17 · Visoms lytims · Atnaujinta 2026-08-03 · NCT06100289An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
- Washington Gastroenterology, Tacoma
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 64 · Visoms lytims · Atnaujinta 2026-07-09 · NCT06398626A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Multicare Health System Institute for Research and Innovation, Tacoma
Renkami dalyviai3 fazė
Amžius nuo 2 iki 17 · Visoms lytims · Atnaujinta 2026-06-22 · NCT06405087Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)
- Seattle Children's Hospital, Seattle
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 6 iki 21 · Visoms lytims · Atnaujinta 2026-04-24 · NCT06315179A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Bellevue
- Mirador Therapeutics Selected Site, Silverdale
- Mirador Therapeutics Selected Site, Tacoma
Renkami dalyviai2 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-03-12 · NCT07113522Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.